![Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei]](/content/dam/novonordisk/esperoctpro/global/esperoct-logo.png){kind=logo}
- 0 thrombotic events1,2
- Observed inhibitor development is consistent with the rate reported in epidemiologic studies (0.15 per 100 patient years)3
- One PTP with an intron 22 inversion developed a FVIII inhibitor1,2,a
- No development of neutralizing anti-PEG antibodies nor hypersensitivity to PEG1,b
COUNT ON A PROVEN SAFETY PROFILE
COUNT ON A PROVEN SAFETY PROFILE
The safety of Esperoct® has been studied across 5 prospective, multi-center clinical trials.1
ESPEROCT® HAS BEEN STUDIED IN:
aAn 18-year-old African-American male with an intron 22 inversion developed a low titer inhibitor after 93 Esperoct® exposure days that subsequently rose to 13.5 Bethesda units, prompting withdrawal from the study. There was no change in efficacy, and the inhibitor eventually went away on its own (without use of ITI).2
bAnti-PEG antibodies of no clinical consequence were detected in 45 subjects, 32 of whom had preexisting anti-PEG antibodies.1
pathfinder™ was the longest and largest extended half-life clinical trial program, evaluating the efficacy and safety of Esperoct® in over 270 patients with hemophilia A worldwide.1
ADVERSE REACTIONS
In clinical trials, the most frequently reported adverse reactions with incidence ≥1% were:1
RECOMBINANT MANUFACTURING
Esperoct® is a recombinant factor VIII treatment made without human blood, plasma, or proteins.1
What are the latest recommendations?
The National Hemophilia Foundation’s Medical and Scientific Advisory Council (MASAC) names recombinant factor VIII products as the recommended treatment of choice for patients with hemophilia A.4
Reconstitute in just a few steps.
With MixPro®, it’s as quick as attach, twist, and mix.1
Starting patients on Esperoct®.
Novo Nordisk offers support programs to help qualifying patients get started.
